High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
6.79B
+3.78%
2.138
-0.08%
5.99B
+4.33%
1.996
+6.18%
6.16B
+3.75%
1.964
+9.13%
Estimates Revision
The market is revising Downward the revenue expectations for Danaher Corporation (DHR) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 7.89%.
Revenue Estimates for FY2025
Revise Downward
-0.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.74%
In Past 3 Month
Stock Price
Go Up
+7.89%
In Past 3 Month
14 Analyst Rating
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 243.45 USD with a low forecast of 220.00 USD and a high forecast of 260.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
3 Hold
0 Sell
Strong Buy
Current: 225.510
Low
220.00
Averages
243.45
High
260.00
Current: 225.510
Low
220.00
Averages
243.45
High
260.00
Wells Fargo
Equal Weight
maintain
$205 -> $230
2025-10-23
Reason
Wells Fargo
Price Target
$205 -> $230
2025-10-23
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Danaher to $230 from $205 and keeps an Equal Weight rating on the shares. The firm notes the company reaffirmed its 2025 EPS guide, despite lowering Q4 organic growth. Initial 2026 outlook calls for positive high single digit EPS growth, even at low-end of +3%-6% core revenue growth, which seems to leave room for upside on Life Sci, OP margin and capital allocation fronts.
TD Cowen
Buy
upgrade
$250 -> $260
2025-10-22
Reason
TD Cowen
Price Target
$250 -> $260
2025-10-22
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Danaher to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following Q3 results and said accelerated cost cuts into what could be an easier recovery in 2026 offered a clearing event for believers in the company's bioprocess-driven story despite a mixed print/guide.
Baird
NULL
to
Outperform
maintain
$236 -> $247
2025-10-22
Reason
Baird
Price Target
$236 -> $247
2025-10-22
maintain
NULL
to
Outperform
Reason
Baird raised the firm's price target on Danaher to $247 from $236 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
BofA
analyst
Buy
downgrade
$230 -> $220
2025-09-22
Reason
BofA
analyst
Price Target
$230 -> $220
2025-09-22
downgrade
Buy
Reason
BofA lowered the firm's price target on Danaher to $220 from $230 and keeps a Buy rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to "normal."
RBC Capital
Outperform
maintain
$250 -> $241
2025-09-02
Reason
RBC Capital
Price Target
$250 -> $241
2025-09-02
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Danaher to $241 from $250 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with "more realistic" multiples, the analyst tells investors in a research note. September isn't a great month to own healthcare, and with a rebound still 2-3 quarters away, this isn't the time to broadly own the sector, RBC added.
Wells Fargo
Equal Weight
maintain
$210 -> $205
2025-07-23
Reason
Wells Fargo
Price Target
$210 -> $205
2025-07-23
maintain
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Danaher to $205 from $210 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat/raise on EPS, while also leaving another about +15c-20c in its back pocket. Bioprocess continues to show a solid recovery, while LS should improve in the second half of the year. Pharma and China commentary was positive, Wells adds, arguing that CFO transition seems manageable.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Danaher Corp (DHR.N) is 27.24, compared to its 5-year average forward P/E of 28.70. For a more detailed relative valuation and DCF analysis to assess Danaher Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
28.70
Current PE
27.24
Overvalued PE
32.10
Undervalued PE
25.30
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
22.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
25.05
Undervalued EV/EBITDA
20.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.05
Current PS
220.44
Overvalued PS
31.20
Undervalued PS
-13.09
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased306.25%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
DHR News & Events
Events Timeline
(ET)
2025-10-21
09:55:01
Significant Early Gainers in Liquid Options on October 21st
2025-10-21
06:08:35
Danaher supports FY25 EPS forecast of $7.70-$7.80, aligning with consensus of $7.78.
2025-10-21
06:07:20
Danaher announces Q3 adjusted earnings per share of $1.89, surpassing consensus estimate of $1.72
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/f4f6d9d160c4dedde1fa522fc151f95093be1a183f4a4aeb7d6e4b61fd8c859c.png)
Preview
3.0
11-18TipRanks3 Stocks Indicating 'Buy Now' Opportunities on Technical Charts
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/eb71eecc61d9e4d00f2c336e0d9da2843c26a6c1ba68611cb99f8d13e671a7bb.jpg)
Preview
3.0
11-15NASDAQ.COMIn-Depth Fundamental Analysis of DHR by Martin Zweig
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3267b6d9603b75f8969eee0359c929caa569a51d5591a754f4e306fe6fe26b6e.jpg)
Preview
3.0
11-13NASDAQ.COMDHR Stock Analysis Using Factor-Based Approach - Martin Zweig
Sign Up For More News
People Also Watch
FAQ
What is Danaher Corp (DHR) stock price today?
What is Danaher Corp (DHR)'s business?
What is the price predicton of DHR Stock?
What is Danaher Corp (DHR)'s revenue for the last quarter?
What is Danaher Corp (DHR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Danaher Corp (DHR)'s fundamentals?
How many employees does Danaher Corp (DHR). have?